|
Training Program in Cancer Biology
|
5T32CA078207-19
|
$554,252
|
AARONSON, STUART
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Preclinical analyses of advanced prostate cancer in genetically-engineered mice
|
2R01CA173481-06
|
$385,883
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
A biomarker-driven strategy to guide the use of radiotherapy in non-small cell lung cancer
|
1R37CA222294-01A1
|
$366,000
|
ABAZEED, MOHAMED
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Development of personalized surgical algorithms for muscle-invasive bladder cancer patients
|
5R21CA218976-02
|
$238,815
|
ABBOSH, PHILIP
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
Novel platform linking cancer-specific glycosylation with cell signaling outcomes
|
1R21CA229044-01
|
$225,250
|
ABBOTT, KAREN
|
UNIV OF ARKANSAS FOR MED SCIS
|
|
Glycomics Laboratory for the Development of Ovarian Cancer Biomarkers
|
1U01CA226055-01
|
$768,101
|
ABBOTT, KAREN
|
UNIV OF ARKANSAS FOR MED SCIS
|
|
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
|
3UM1CA186704-04S1
|
$170,500
|
ABBRUZZESE, JAMES
|
DUKE UNIVERSITY
|
|
Evaluation of an OCA2 enhancer variant as a modifier of the phenotype of BAP1-Tumor predisposition syndrome
|
1R21CA219884-01A1
|
$203,471
|
ABDEL-RAHMAN, MOHAMED
|
OHIO STATE UNIVERSITY
|
|
Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance
|
5R01CA201247-03
|
$511,614
|
ABDEL-WAHAB, OMAR
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Master Regulatory MicroRNAs in Glioblastoma
|
5U01CA220841-02
|
$452,813
|
ABOUNADER, ROGER
|
UNIVERSITY OF VIRGINIA
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Detection of somatic, subclonal and mosaic CNVs from sequencing
|
1U24CA220242-01A1
|
$559,916
|
ABYZOV, ALEXEJ
|
MAYO CLINIC ROCHESTER
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-04
|
$2,184,301
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Nanoparticle mediated microenvironmental targeting of CCL3 signaling for the treatment of acute myelogenous leukemia
|
1F31CA228391-01
|
$42,418
|
ACKUN-FARMMER, MARIAN
|
UNIVERSITY OF ROCHESTER
|
|
Identifying molecular drivers of tumor heterogeneity in pancreatic cancer
|
1F31CA224792-01A1
|
$36,672
|
ADAMS, CHRISTINA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
WalkIT: Neighborhood walkability and moderation of adaptive walking interventions
|
5R01CA198915-04
|
$568,727
|
ADAMS, MARC
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Giant Macrophage-like Cells as a blood-based Biomarker for Lung Cancer Recurrence
|
5R43CA206840-02
|
$67,150
|
ADAMS, DANIEL
|
CREATV MICROTECH, INC.
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Discovery and Characterization of Mutations in Breast and Ovarian Cancers
|
5R50CA211280-03
|
$215,047
|
ADAMSON, AARON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
AFRICAN FEMALE BREAST CANCER EPIDERMIOLOGY (AFBRECANE) STUDY
|
5U01HG009784-02
|
$85,000
|
ADEBAMOWO, CLEMENT
|
INSTITUTE OF HUMAN VIROLOGY
|
|
Genetic identification of novel mTORC1 regulators and homeostatic signaling mechanisms
|
1F31CA228241-01
|
$44,524
|
ADELMANN, CHARLES
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
|
University of North Carolina Womens Interagency HIV Study UNC WIHS
|
3U01AI103390-05S1
|
$60,652
|
ADIMORA, ADAORA
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Probing the role of the IRE1alpha-XBP1 pathway in normal and malignant hematopoiesis
|
5K22CA218467-02
|
$192,575
|
ADORO, STANLEY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
|
1R01CA236615-01
|
$392,764
|
ADUSUMILLI, PRASAD
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Developing targeted activatable peptides to amplify radiosensitizer delivery
|
5R03CA219744-02
|
$77,500
|
ADVANI, SUNIL
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
5R03CA212798-02
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
5R03CA219336-02
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Leveraging polyamine metabolic stress as a novel therapy for prostate cancer
|
4K00CA212455-03
|
$69,749
|
AFFRONTI, HAYLEY
|
UNIVERSITY OF PENNSYLVANIA
|
|
Genetics of Graft-versus-Host Disease
|
1R01CA231141-01
|
$265,229
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
New Roles for the WTX Tumor Suppressor and Endocytosis in WNT signaling
|
1F31CA228289-01
|
$34,190
|
AGAJANIAN, MEGAN
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
3R01CA195708-05S1
|
$94,087
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
|
5R01CA140368-07
|
$369,313
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
5R01CA195708-05
|
$382,616
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Targeting SHP2 as a precision medicine for the treatment of HER2-positive breast cancer
|
1R01CA213996-01A1
|
$343,125
|
AGAZIE, YEHENEW
|
WEST VIRGINIA UNIVERSITY
|
|
Policy- and Provider-Level Determinants of Human Papillomavirus Vaccination Disparities Among Young U.S. Women
|
1K01CA234226-01
|
$158,403
|
AGENOR, MADINA
|
TUFTS UNIVERSITY MEDFORD
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems
|
1R01CA227136-01A1
|
$454,956
|
AGHI, MANISH
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Analysis of HCC CTC Phenotype for Liver Transplant Candidate Selection
|
1R21CA216807-01A1
|
$203,254
|
AGOPIAN, VATCHE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
|
5K08CA218420-02
|
$177,120
|
AGUIRRE, ANDREW
|
DANA-FARBER CANCER INST
|
|
Functional Determinants of Metastatic Dormancy
|
5R01CA109182-15
|
$423,844
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Epigenetic and microenvironmental regulation of dormant disseminated cancer
|
5R01CA218024-02
|
$428,136
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Assessment of sensory gating, attention, and executive control in breast cancer
|
1R01CA218496-01A1
|
$687,576
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S1
|
$54,859
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S2
|
$188,884
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
|
1R43CA228813-01A1
|
$300,000
|
AHMED, HAFIZ
|
GLYCOMANTRA, INC.
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|